This company has been acquired
Opiant Pharmaceuticals (OPNT) Stock Overview
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
OPNT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Opiant Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.65 |
| 52 Week High | US$28.15 |
| 52 Week Low | US$7.34 |
| Beta | 0.83 |
| 1 Month Change | 3.10% |
| 3 Month Change | 2.38% |
| 1 Year Change | -22.31% |
| 3 Year Change | 70.80% |
| 5 Year Change | 1.77% |
| Change since IPO | -82.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| OPNT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.3% | 0.9% | -0.1% |
| 1Y | -22.3% | 48.1% | 11.9% |
Return vs Industry: OPNT underperformed the US Pharmaceuticals industry which returned -3.7% over the past year.
Return vs Market: OPNT underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| OPNT volatility | |
|---|---|
| OPNT Average Weekly Movement | 1.5% |
| Pharmaceuticals Industry Average Movement | 8.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: OPNT has not had significant price volatility in the past 3 months.
Volatility Over Time: OPNT's weekly volatility has decreased from 19% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 38 | Roger Crystal | www.opiant.com |
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.
Opiant Pharmaceuticals, Inc. Fundamentals Summary
| OPNT fundamental statistics | |
|---|---|
| Market cap | US$108.80m |
| Earnings (TTM) | -US$33.09m |
| Revenue (TTM) | US$22.34m |
Is OPNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPNT income statement (TTM) | |
|---|---|
| Revenue | US$22.34m |
| Cost of Revenue | US$29.45m |
| Gross Profit | -US$7.11m |
| Other Expenses | US$25.97m |
| Earnings | -US$33.09m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.28 |
| Gross Margin | -31.85% |
| Net Profit Margin | -148.12% |
| Debt/Equity Ratio | 67.1% |
How did OPNT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/03 09:25 |
| End of Day Share Price | 2023/03/01 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Opiant Pharmaceuticals, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Brandon Folkes | Cantor Fitzgerald & Co. |
| Carl Byrnes | Northland Capital Markets |